U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2004
216
Substance Class Protein
Created
by admin
on Mon Mar 31 18:34:49 GMT 2025
Edited
by admin
on Mon Mar 31 18:34:49 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin MOUSE CHIMERIC
Sequence Type COMPLETE
Record UNII
PQX0D8J21J
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
Cetuximab
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
CETUXIMAB (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
C-225
Code English
ERBITUX
Brand Name English
IMCC225
Code English
Cetuximab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1 (HUMAN-MOUSE MONOCLONAL C225 .GAMMA.1-CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL C225 .KAPPA.-CHAIN, DIMER
Common Name English
CETUXIMAB [JAN]
Common Name English
IMCC-225
Code English
IMC-C225
Code English
C225
Code English
cetuximab [INN]
Common Name English
IMC-225
Code English
Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain), disulfide with human-mouse monoclonal C225 ?-chain, dimer
Common Name English
CETUXIMAB (GENETICAL RECOMBINATION) [JAN]
Common Name English
FV REGIONS OF MURINE ANTI-EGFR ANTIBODY WITH HUMAN IGG1 HEAVY AND KAPPA LIGHT CHAIN CONSTANT REGIONS, MW 152000
Common Name English
CETUXIMAB [PURPLE BOOK CDER]
Common Name English
IMMUNOGLOBULIN G1 (HUMAN-MOUSE MONOCLONAL C225 .GAMMA.1-CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL C225 .KAPPA.-CHAIN, DIMER
Common Name English
CETUXIMAB [MI]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN-MOUSE MONOCLONAL C225 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL C225 .KAPPA.-CHAIN, DIMER
Common Name English
MOAB C225
Code English
CETUXIMAB [MART.]
Common Name English
CETUXIMAB [USAN]
Common Name English
EXTRACELLULAR DOMAIN HUMAN EGFR BINDING RECOMBINANT, HUMAN/MOUSE CHIMERIC MONOCLONAL ANTIBODY
Common Name English
CETUXIMAB [HSDB]
Common Name English
CETUXIMAB [VANDF]
Common Name English
CETUXIMAB [EMA EPAR]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 237907
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NDF-RT N0000020010
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
WHO-ATC L01XC06
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
WHO-VATC QL01XC06
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
LIVERTOX NBK547908
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NDF-RT N0000175664
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NDF-RT N0000020010
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NCI_THESAURUS C133878
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NCI_THESAURUS C1742
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
EMA ASSESSMENT REPORTS ERBITUX (AUTHORIZED: COLORECTAL NEOPLASMS, HEAD AND NECK NEOPLASMS)
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
FDA ORPHAN DRUG 132700
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
Code System Code Type Description
MESH
C411189
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
DAILYMED
PQX0D8J21J
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
EVMPD
SUB01178MIG
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
INN
7906
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
FDA UNII
PQX0D8J21J
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
SMS_ID
100000091438
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
RXCUI
318341
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY RxNorm
EVMPD
SUB127096
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
WIKIPEDIA
CETUXIMAB
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
DRUG BANK
DB00002
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
NCI_THESAURUS
C1723
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
EPA CompTox
DTXSID0040830
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
IUPHAR
6882
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
HSDB
7454
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
DRUG CENTRAL
4954
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
USAN
KK-51
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
MERCK INDEX
m3296
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL1201577
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
CAS
205923-56-4
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
LACTMED
Cetuximab
Created by admin on Mon Mar 31 18:34:49 GMT 2025 , Edited by admin on Mon Mar 31 18:34:49 GMT 2025
PRIMARY
From To
1_22 1_95
1_146 1_202
1_222 3_214
1_228 2_228
1_231 2_231
1_263 1_323
1_369 1_427
2_22 2_95
2_146 2_202
2_222 4_214
2_263 2_323
2_369 2_427
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_88
N 1_299
N 2_88
N 2_299
Related Record Type Details
ABP-494
SUB_CONCEPT->SUBSTANCE
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
Cetuximab Beta
BIOSIMILAR -> PARENT
Cetuximab Beta
SUB_CONCEPT->SUBSTANCE
PERTUZUMAB
TARGET -> INHIBITOR
EPIDERMAL GROWTH FACTOR RECEPTOR
TARGET -> INHIBITOR
BINDING
Ficerafusp Alfa
CONJUGATE->CONJUGATE COMPONENT
Related Record Type Details
Cetuximab
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966